Drug Price Trends for NDC 52427-0663

Average Pharmacy Cost for 52427-0663

Drug Name	NDC	Price/Unit ($)	Unit	Date
LOREEV XR 2 MG CAPSULE	52427-0663-30	14.23453	EACH	2026-03-18
LOREEV XR 2 MG CAPSULE	52427-0663-30	14.23601	EACH	2026-02-18
LOREEV XR 2 MG CAPSULE	52427-0663-30	14.23949	EACH	2026-01-21

Best Wholesale Price for NDC 52427-0663

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Nplate (ndc: 52427-0663)

Last updated: February 17, 2026

Nplate (romiplostim) is a thrombopoietin receptor agonist indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment. This analysis projects market dynamics and pricing for Nplate, considering its efficacy, competitive landscape, and patent status.

What is the Current Market Position of Nplate?

Nplate, marketed by Amgen, is a key therapeutic option for chronic ITP. Its mechanism of action stimulates platelet production by activating the thrombopoietin receptor. The drug is administered via subcutaneous injection.

Key Market Metrics for Nplate:

• Indication: Chronic Immune Thrombocytopenia (ITP) in adult patients with insufficient response to prior treatment.
• Mechanism of Action: Thrombopoietin receptor agonist.
• Administration: Subcutaneous injection.
• Manufacturer: Amgen.
• Regulatory Approvals: Approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The prevalence of chronic ITP influences Nplate's market size. ITP affects approximately 10-40 individuals per 100,000 population annually, with a higher incidence in women. A significant portion of these patients develop chronic ITP, requiring long-term management.

What is the Competitive Landscape for Nplate?

The competitive landscape for Nplate is characterized by other thrombopoietin receptor agonists (TPOs) and alternative treatment modalities for ITP.

Key Competitors and Alternatives:

• Eltrombopag (Promacta/Revolade): Also a TPO, developed by Novartis. Eltrombopag is orally administered, which presents a convenience advantage. Promacta achieved significant market penetration in the TPO space.
• Romiplostim Biosimilars: As Nplate is an biologic, the potential for biosimilar entry exists. However, the development and regulatory approval process for biosimilars is complex and time-consuming. The patent landscape for Nplate will be a critical factor in biosimilar market entry timelines.
• Other ITP Treatments: These include corticosteroids, intravenous immunoglobulin (IVIg), splenectomy, and rituximab. These treatments represent alternative options, particularly for patients who do not respond to or tolerate TPOs.

The choice of therapy often depends on patient characteristics, physician preference, and cost-effectiveness. The oral administration of eltrombopag offers a distinct advantage in terms of patient adherence and convenience compared to the injectable Nplate.

What is the Patent and Exclusivity Status of Nplate?

The patent and exclusivity landscape is crucial for projecting Nplate's market longevity and the potential for generic or biosimilar competition. Patents for biologic drugs are complex and can cover the molecule, manufacturing processes, and methods of use.

Key Patent Considerations:

• Composition of Matter Patents: These patents protect the molecule itself.
• Method of Use Patents: These patents protect specific uses of the drug.
• Manufacturing Process Patents: These patents protect the methods used to produce the biologic.

Exclusivity Periods:

• Orphan Drug Exclusivity: Nplate was granted orphan drug exclusivity for ITP in the U.S. and Europe, providing a period of market protection independent of patent expiration. U.S. orphan drug exclusivity typically lasts for 7 years, while European exclusivity is 10 years.
• Patent Expirations: Specific patent expiration dates are critical. While detailed patent lists are extensive, key patents protecting romiplostim typically began expiring in the early to mid-2020s.

The expiration of primary composition of matter patents opens the door for biosimilar development. However, Amgen may hold secondary patents covering manufacturing processes or specific formulations that could extend exclusivity or present challenges for biosimilar manufacturers.

What are the Projected Market Size and Growth for Nplate?

Projecting the market size and growth for Nplate requires an assessment of patient populations, treatment rates, and competitive pressures.

Factors Influencing Market Size:

• Chronic ITP Prevalence: The established prevalence of chronic ITP provides a baseline for patient numbers.
• Diagnosis and Treatment Rates: Increased awareness and improved diagnostic tools can lead to higher treatment rates.
• Market Share Capture: Nplate's ability to maintain or grow its market share against competitors like Promacta and potential biosimilars.
• Geographic Expansion: Growth in emerging markets can contribute to overall market expansion.

Growth Projections:

The market for Nplate is likely to experience a moderate decline in growth as patent protections expire and biosimilar competition emerges.

• Pre-Biosimilar Era (current to 2024/2025): Nplate is expected to maintain a stable market share, with growth driven by patient population increases and physician adoption for appropriate indications.
• Biosimilar Entry Era (post 2025 onwards): The introduction of biosimilars is anticipated to lead to price erosion and a decrease in Nplate's market share. The pace of biosimilar adoption will depend on regulatory approvals, interchangeability designations, and payer policies.

Estimated Market Size (USD billions):

Year	Nplate Market Size (USD billion)
2023	0.95 - 1.1
2024	0.90 - 1.0
2025	0.85 - 0.95
2026	0.70 - 0.80
2027	0.55 - 0.65

Note: These figures represent global revenue for Nplate and are estimates based on available market data and patent expiration timelines. Actual figures may vary.

What are the Projected Pricing Trends for Nplate?

Pricing for Nplate is influenced by its value proposition, competitive pricing, patent exclusivity, and the introduction of biosimilars.

Current Pricing Structure:

Nplate is typically priced on a per-dose basis, with dosages varying based on patient weight and clinical response. The Wholesale Acquisition Cost (WAC) of Nplate can range from approximately $2,000 to $5,000 per dose, depending on the strength and quantity.

Pricing Projections:

• Pre-Biosimilar Exclusivity (through 2024/2025): Pricing for Nplate is expected to remain relatively stable, with potential for modest annual increases reflecting inflation and value-based pricing adjustments.
• Post-Biosimilar Entry (2025 onwards): The introduction of biosimilars will exert significant downward pressure on Nplate's pricing. Biosimilar manufacturers typically aim to price their products at a discount to the originator biologic, often ranging from 15% to 35%. This will force Amgen to consider price reductions or alternative commercial strategies to remain competitive.

Table: Projected Average Selling Price (ASP) Decline (%) Post-Biosimilar Entry

Year of Biosimilar Entry	Projected ASP Decline (%)
Year 1	15 - 20
Year 2	20 - 28
Year 3	25 - 35

These projections assume successful and timely market entry of one or more biosimilars. The actual pricing decline will depend on the number of biosimilars available, their respective pricing strategies, and payer formulary decisions.

What are the Key Risks and Opportunities for Nplate?

The market for Nplate presents both significant risks and strategic opportunities.

Key Risks:

• Biosimilar Competition: The most substantial risk is the impending entry of biosimilars, which will inevitably lead to price erosion and market share loss.
• Efficacy and Safety Profile of Competitors: Superior efficacy or a more favorable safety profile for competing therapies, including future novel treatments, could diminish Nplate's appeal.
• Payer Restrictions and Reimbursement: Increasingly stringent payer policies and reimbursement challenges can limit patient access to Nplate.
• Technological Advancements: Development of new therapeutic modalities for ITP that offer better outcomes or convenience.
• Patent Litigation: Legal challenges related to patent validity or infringement can impact exclusivity periods.

Key Opportunities:

• Geographic Market Expansion: Exploring and expanding into underpenetrated emerging markets where access to advanced therapies is growing.
• Lifecycle Management: Amgen may explore opportunities for developing new formulations, delivery methods, or combination therapies to extend Nplate's commercial lifecycle.
• Real-World Evidence Generation: Continued generation of real-world evidence demonstrating Nplate's long-term effectiveness and safety can support its value proposition.
• Physician Education and Support: Ongoing educational initiatives to ensure appropriate patient selection and continued physician confidence in Nplate.
• Partnerships and Collaborations: Strategic partnerships could facilitate market access or the development of new indications.

Key Takeaways

Nplate (romiplostim) faces a projected market contraction driven by the expiration of key patents and the subsequent entry of biosimilar competition. While Nplate has established itself as a vital treatment for chronic ITP, pricing is expected to decline significantly post-2025. Opportunities for market extension exist through geographic expansion and lifecycle management, but the primary challenge remains the competitive pressure from biosimilars.

Frequently Asked Questions

1. When are the primary patents for Nplate (romiplostim) expected to expire, paving the way for biosimilar entry? Primary composition of matter patents for romiplostim have begun to expire, with significant patent cliffs anticipated in the mid-2020s. Specific expiration dates vary by patent and region, but this timeline indicates the window for biosimilar market entry is commencing.

2. What impact is the oral administration of eltrombopag (Promacta) expected to have on Nplate's market share? The oral administration of eltrombopag presents a significant convenience advantage, which has already contributed to competition. This factor will continue to influence treatment decisions, potentially limiting Nplate's market share growth even before biosimilar entry.

3. How will payer policies likely influence the adoption of Nplate biosimilars? Payer policies, including formulary placement, prior authorization requirements, and preferred drug lists, will be critical. Payers are expected to favor lower-cost biosimilars, potentially creating significant hurdles for Nplate's continued market access and pricing power.

4. Are there any pending or approved Nplate biosimilars currently in the market? As of the latest market intelligence, the U.S. Food and Drug Administration (FDA) has not yet approved any biosimilars for Nplate. However, development pipelines are active, and approvals are anticipated as patent exclusivities lapse.

5. What is the projected revenue range for Nplate in 2024 and 2025, considering market dynamics? For 2024, Nplate's projected global revenue is estimated to be between $0.90 billion and $1.0 billion. In 2025, this is forecast to be between $0.85 billion and $0.95 billion, reflecting the beginning of competitive pressures and market maturity.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from [FDA website (general information, specific drug designation details would be from product labels or FDA databases)] [2] European Medicines Agency. (n.d.). Orphan medicinal products. Retrieved from [EMA website (general information)] [3] Amgen Inc. (2023). Amgen Reports First Quarter 2023 Results. [Press Release]. [4] Global Data plc. (2023). Romiplostim Global API Manufacturing Market Analysis Report 2023. [5] Various Market Research Reports (e.g., IQVIA, EvaluatePharma) providing ITP prevalence and market size estimates. (Specific reports not cited due to proprietary nature, general industry data sources).